摘要目的:观察接受程序性死亡蛋白1（PD-1）抑制剂治疗患者出现的皮肤毒性不良反应，总结其护理措施，为采取相应管理措施提供依据。方法:采用便利抽样法，收集2019年2—10月在北京协和医学院肿瘤医院内科接受PD-1抑制剂治疗的94例患者作为研究对象，将其中出现皮肤毒性反应的37例（39.4%）患者作为研究对象。观察与评估皮肤毒性，同时给予健康教育与心理护理、皮肤毒性反应的护理。结果:37例患者中，34例（91.9%）为皮肤毒性G1级患者，未给予药物治疗，皮疹消退后按照原计划治疗；2例（5.4%）为皮肤毒性G2级患者，药物治疗后皮疹消退，可见散在色素沉着，按照计划进行原方案治疗；1例（2.7%）为皮肤毒性G4级患者，请皮肤科、感染科会诊，体温正常，皮肤黏膜破溃、结痂、脱落，患者病情好转出院。结论:患者接受PD-1抑制剂免疫治疗后可出现不同程度的免疫相关性皮肤毒性反应，需要临床医生及护士进行规范化的治疗及护理，以改善患者生活质量。

abstractsObjective:To observe the adverse effects of skin toxicity after the administration of programmed cell death protein 1 (PD-1) inhibitor, summarize the nursing measures, and provide a basis for taking corresponding management measures.Methods:Totally 94 patients who were treated with PD-1 inhibitor in Cancer Hospital of Chinese Academy of Medical Sciences between February and October 2019 were selected by convenient sampling, among whom 37 cases (39.4%) with skin toxicity reaction were included as the research subjects. Their skin toxicity was observed and assessed. Meanwhile, health education, psychological counseling and nursing care for skin toxicity reaction were provided to them.Results:Of the 37 patients, 34 (91.9%) had G1 skin toxicity and were not treated with drugs. After the rash subsided, they were treated according to the original plan. 2 (5.4%) had G2 skin toxicity, whose rash subsided after drug treatment, with scattered pigmentation. They were treated according to the original plan. 1 (2.7%) had G4 skin toxicity. The medical staff from the Dermatology Department and the Infection Department were consulted. The body temperature was normal, and the skin and mucous membranes were ruptured, crusted and detached. The patient was discharged after the condition was improved.Conclusions:After receiving PD-1 inhibitor immunotherapy, patients may have different degrees of immune-related skin toxicity reactions, which requires clinicians and nurses to carry out standardized treatment and care to improve their quality of life.